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A final impetus for
change was that
the guidelines
themselves had be-
come more compli-
cated with each
revision, with am-
biguous recommen-
dations for which
specific patient and
which particular
procedure required
the prophylaxis.t has been more than 50 years since the American Heart Association (AHA) first
made recommendations for the use of antimicrobial agents to prevent infective en-
docarditis (IE). The first AHA document on this subject was published in 1955
nd has been followed by 9 revisions outlining which patients, which procedures, and
hat antibiotics should be used to prevent IE. Since that time, there have been extensive
fforts by physicians, dentists, and patients to ensure that everyone at risk for developing
ndocarditis would follow these guidelines and receive the proper regimen of antibiotics
rior to selected dental or surgical procedures.
However, in 2007 the AHA issued guidance for IE prophylaxis that greatly simplified
he recommendations and proposed substantive changes—changes that would affect
undreds of thousands of patients in the U.S. alone (1). Since then, we, and most likely
ll of you, have been barraged by our surgical and dental colleagues and patients with
nquiries—“Are you sure this is the right thing to do? Would you mind putting the rec-
mmendation in writing before I proceed?”
hat Evidence for Change?
hy were these significant changes introduced, and why wasn’t there a heads up that
uch a dramatic change was coming? It helps to remember that the prior rationale for
sing antimicrobial prophylaxis was that antibiotics would control bacteremia at the
ime of the procedure and thus prevent IE. However, this treatment rationale was
ased primarily on expert opinion and support from a few case-controlled and de-
criptive studies. There has never been a controlled, randomized study that evaluated
his strategy.
In contrast, some have noted the lack of consistent association between having an
nterventional procedure and the development of IE, and they have questioned the
linical effectiveness of antibiotic prophylaxis. Some have asked whether the risk of
iving antibiotics outweighed the small, perhaps nonexistent benefit. It has even
een suggested that the risk of a serious allergic reaction to amoxicillin is greater
han the risk of contracting IE.
A report from the Cochrane Collaboration in 2004 concluded, “There is no evi-
ence about whether penicillin prophylaxis is effective or ineffective against IE in
eople at risk who are about to undergo an invasive dental procedure. There is lack
f evidence to support published guidelines in this area, and it is not clear whether
he potential harm and costs of penicillin administration outweigh any beneficial ef-
ect” (2).
Evidence is now moving from “procedure-related bacteremia” toward “cumulative
acteremia” as the more likely cause of most cases of IE. For instance, daily activi-
ies such as tooth brushing are estimated to produce bacteremia 6 million times
igher than a single tooth extraction. Thus, continued episodic bacteremia due to
oor dentition may pose a much greater risk for the development of IE than a single
ental procedure.
t
s
p
p
R
O
F
c
t
c
a
b
g
a
r
A
w
o
r
t
•
•
•
f
m
a
o
i
w
w
b
s
t
s
b
n
r
g
p
v
t
e
a
o
S
o
m
T
o
f
e
t
G
A
h
l
d
f
t
B
t
t
r
w
a
a
C
A
u
r
c
l
s
e
b
c
p
p
g
o
b
t
b
i
u
v
n
p
b
l
o
r
496 Weaver et al. JACC Vol. 52, No. 6, 2008
President’s Page August 5, 2008:495–7A final impetus for change was that the guidelines
hemselves had become more complicated with each revi-
ion, with ambiguous recommendations for which specific
atient and which particular procedure required the pro-
hylaxis.
ecommendations Shift Emphasis
n the basis of these controversies, the AHA Rheumatic
ever, Endocarditis, and Kawasaki Disease Committee
onvened a group of national and international experts in
he field, including cardiologists, infectious disease spe-
ialists, pediatricians, and dentists. This writing group
nalyzed relevant literature regarding procedural-related
acteremia and IE, in vitro susceptibility data of the or-
anisms causing IE, and results of prophylactic studies
nd animal models of experimental IE, as well as any ret-
ospective or prospective studies in the prevention of IE.
fter several years of discussion and debate within the
riting group combined with input from experts from
ther learned societies, the new recommendations were
eleased. The recommendations were clear, simple, and
o the point:
Infective endocarditis prophylaxis should be given only to a
high-risk subgroup of patients prior to dental procedures
that involve manipulation in gingival tissue or periapical
region of the teeth or perforation of the oral mucosa.
High-risk patients include only those with a: 1) prosthetic
cardiac valve; 2) previous infective endocarditis; 3) com-
plex congenital heart disease; and 4) valvulopathy follow-
ing cardiac transplantation.
Infective endocarditis prophylaxis is not recommended prior
to gastrointestinal or genitourinary procedures.
These recommendations represented a major departure
rom the traditional practice of IE prophylaxis. The com-
ittee wanted to shift emphasis away from a focus on
ntibiotic prophylaxis prior to a single procedure to rec-
mmendations that place a much greater emphasis on
mproved access to dental care and oral health in patients
ith underlying cardiac conditions. “High-risk” patients
ere defined not on the basis of an increased risk for IE,
ut rather on an increased risk of an adverse outcome
hould they develop endocarditis.
The new guideline, which generated considerable con-
roversy among physicians, dentists, and patients, repre-
ented a paradigm shift from traditional dogma and was
ased on expert consensus rather than on any compelling
ew data or evidence. In fact, one might argue that it was
eally a consensus document—and not an evidence-based
uideline.
Health care providers have been reluctant to stop a
ractice that they had been taught was necessary to pre-
ent a devastating event and that they have ingrained in
heir patients who have underlying structural heart dis-
ase. Even the experts in this practice area have been un- able to reach agreement or comfort with these new rec-
mmendations. Other societies, such as the British
ociety for Antimicrobial Chemotherapy, have also rec-
mmended simplified guidelines, although not at the
agnitude of change suggested by the AHA (3).
The American College of Cardiology (ACC)/AHA
ask Force on Practice Guidelines is providing an update
n IE prophylaxis for the 2006 ACC/AHA Guidelines
or the Management of Patients with Valvular Heart Dis-
ase (VHD) (4), and we should probably anticipate that
he soon to-be-published Adult Congenital Heart Disease
uidelines will also include some sort of update. The
CC/AHA VHD Guidelines, as well as several others,
ave always referenced the AHA IE Prophylaxis Guide-
ine. The writing committees for the VHD Focused Up-
ate and Guidelines, which comprise physicians selected
or their expertise in VHD, were asked to comment on
he new IE recommendations released by the AHA.
ased on their review of the initial 2007 AHA document,
he AHA published an errata document in April 2008
hat changed some of the language in order to clarify the
ecommendations. The ACC/AHA Focused Update,
hich will be published in JACC and Circulation soon,
ddresses the recommendations as they apply to the man-
gement of VHD.
ontroversy or Different Expectations?
mong many physicians and experts, controversy contin-
es over these changes. Some firmly believe that the new
ecommendations should clearly be followed without ex-
eption. However, others argue that for antibiotic prophy-
axis “the lack of evidence of benefit is not necessarily the
ame as lack of benefit” and that insufficient new evidence
xists to justify such a radical change in policy. It has
een argued that there is an illogicality of the fudge in
ontinuing to recommend prophylaxis for very high risk
atients, as endocarditis is always dangerous. If antibiotic
rophylaxis is ineffective, why select only a high-risk
roup for prophylaxis?
Despite the controversy and angst that these new rec-
mmendations have generated, there have been some
eneficial outcomes. The document has raised awareness
hat meticulous oral hygiene and routine preventive care
y dentists are of utmost importance in preventing IE
n patients at increased risk. Other sources of contin-
ed bacteremia, such as nail biting, intrauterine de-
ices, acne, and body piercing, are now being recog-
ized and addressed.
The situation we face revolves in part around our ex-
ectations about what represents a guideline. We have
ecome less comfortable in endorsing consensus as a guide-
ine and have come to expect evidence-based data to guide
ur clinical decision-making. Thus, there is no correct
ecommendation, and a state of equipoise currently exists
round this question, which begs for a properly designed
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hould have eliminated the “guideline,” simply explained
he issues, and recommended that you and your patients
ake the final decision regarding treatment while we
wait real evidence.
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